Acelyrin
MSD announces phase 2 results for tulisokibart in moderate to severe hidradenitis suppurativa
Tulisokibart was designed to help address immuno-fibrosis, a key driver of disease progression in HS
LEO Pharma to acquire Replay gene therapy platform
The acquisition will advance innovation for patients with rare skin diseases
Almirall celebrates new offices in China to advance innovation in dermatology
The company’s R&D and commercial expertise represent valuable capabilities for future Chinese partners
UCB releases new data on Bimzelx for hidradenitis suppurativa
The disease affects around 1% of the population in most studied countries
InflaRx reports positive phase 2 results for HS and CSU treatments
Topline results demonstrated treatment efficacy for both conditions
Global Healthy Living Foundation and Medscape Education Join Forces to Bridge the Gap Between Patients and Providers with Immunology Education
UPPER NYACK, N.Y.--(BUSINESS WIRE)--The Global Healthy Living Foundation (GHLF) today announced a new partnership with Medscape Education to advance patient-centered innovation within the Immunology Learning Nexus (Nexus), Medscape’s flagship multi-year...
Almirall and Absci expand AI dermatological drug discovery partnership
The alliance has already led to the delivery of functional antibody leads against a difficult-to-drug target
Johnson & Johnson files FDA application for Tremfya in psoriatic arthritis
Approximately 125 million people globally are living with some form of psoriasis
Apogee Therapeutics’ atopic dermatitis candidate shows promise in phase 2 study
The inflammatory skin condition affects over 26 million people in the US
Honoring the Legacy of Dr. Robert Sidbury, MD, MPH
We are deeply saddened by the recent passing of Dr. Robert Sidbury. Dr. Sidbury was a visionary in pediatric dermatology whose dedication to advancing patient care inspired clinicians, researchers, and...
LEO Pharma gains access to Boehringer’s skin disease drug for €90m upfront
Spevigo is already approved in over 40 countries to treat generalised pustular psoriasis
UCB’s Bimzelx demonstrates lasting efficacy in phase 3 psoriatic arthritis trials
Approximately 125 million people worldwide are affected by some form of psoriasis